1h Free Analyst Time
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis. Speak directly to the analyst to clarify any post sales queries you may have.
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Infectious Disease and Respiratory which include indications Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Dyslipidemia, Hepatitis B, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.
The latest report Free Fatty Acid Receptor 1 - Drugs In Development, 2022, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
- The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
- Caldan Therapeutics Ltd
- Eli Lilly and Co
- Fujian Haixi New Medicine Creation Co Ltd
- Halo Therapeutics Ltd
- Hyundai Pharma Co Ltd
- Ildong Pharmaceutical Co Ltd
- Johnson & Johnson
- Merck & Co Inc
- Scohia Pharma Inc
- Takeda Pharmaceutical Co Ltd
- TiumBio Co Ltd
- Zydus Lifesciences Ltd
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
- fasiglifam - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HLTX-3 - Drug Profile
- Product Description
- Mechanism Of Action
- HOB-047 - Drug Profile
- Product Description
- Mechanism Of Action
- HXP-0057 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IDG-16177 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-2922470 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MK-2305 - Drug Profile
- Product Description
- Mechanism Of Action
- NCE-406 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SCO-267 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- TUG-770 - Drug Profile
- Product Description
- Mechanism Of Action
- ZYDG-2 - Drug Profile
- Product Description
- Mechanism Of Action
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
- Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
- Featured News & Press Releases
- Jun 30, 2021: Ildong Pharmaceutical starts phase 1 study of new diabetes therapy in Germany
- Jun 28, 2021: The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions - American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial
- Apr 21, 2021: Ildong Pharmaceutical applied for clinical plan approval for new diabetes drug in Europe
- Feb 08, 2021: Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models
- Sep 15, 2020: Conference presentation on medicinal chemistry research of GPR40 full agonist (SCO-267)
- Sep 10, 2020: GPR40 full agonist (SCO-267) medicinal chemistry research
- Jul 28, 2020: Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD
- May 10, 2020: Hyundai Pharm's diabetes drug gets FDA approval for phase 2 clinical trial
- Dec 09, 2019: SCOHIA initiates a Phase 1 study of a GPR40 full agonist (SCO-267)
- Jun 17, 2019: Presentation of new preclinical data of SCO-267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions
- Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
- Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions
- Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development
- Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes
- May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Caldan Therapeutics Ltd, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Fujian Haixi New Medicine Creation Co Ltd, 2022
- Pipeline by Halo Therapeutics Ltd, 2022
- Pipeline by Hyundai Pharma Co Ltd, 2022
- Pipeline by Ildong Pharmaceutical Co Ltd, 2022
- Pipeline by Johnson & Johnson, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Scohia Pharma Inc, 2022
- Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Pipeline by TiumBio Co Ltd, 2022
- Pipeline by Zydus Lifesciences Ltd, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Caldan Therapeutics Ltd
- Eli Lilly and Co
- Fujian Haixi New Medicine Creation Co Ltd
- Halo Therapeutics Ltd
- Hyundai Pharma Co Ltd
- Ildong Pharmaceutical Co Ltd
- Johnson & Johnson
- Merck & Co Inc
- Scohia Pharma Inc
- Takeda Pharmaceutical Co Ltd
- TiumBio Co Ltd
- Zydus Lifesciences Ltd
